Keep an eye on Summit Therapeutics (SMMT).
Co-CEO and Executive Chairman Robert Duggan just bought $75 million worth of SMMT at an average price of $22.70 a share.
Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.
Most recently, the company just said that its investigational bispecific antibody, ivonescimab, reduced the risk of disease progression or death by 49%, as compared to Merck’s cancer therapy Keytruda (pembrolizumab) in the first-line treatment of lung cancer patients.